newsfilter
← Latest News
GlobeNewswire·

Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021

Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling Phase 1 clinical trial anticipated to begin during Q4 202